Cargando…
Mouse Models as a Tool for Understanding Progression in Braf(V600E)-Driven Thyroid Cancers
The development of next generation sequencing (NGS) has led to marked advancement of our understanding of genetic events mediating the initiation and progression of thyroid cancers. The NGS studies have confirmed the previously reported high frequency of mutually-exclusive oncogenic alterations affe...
Autores principales: | Landa, Iñigo, Knauf, Jeffrey A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435851/ https://www.ncbi.nlm.nih.gov/pubmed/30784243 http://dx.doi.org/10.3803/EnM.2019.34.1.11 |
Ejemplares similares
-
Telomerase reactivation induces progression of mouse Braf(V600E)-driven thyroid cancers without telomere lengthening
por: Landa, Iñigo, et al.
Publicado: (2023) -
OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022) -
BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018) -
CYP2S1 is a synthetic lethal target in BRAF(V600E)-driven thyroid cancers
por: Li, Yiqi, et al.
Publicado: (2020) -
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)